

Cardiovascular outcome trials in type 2 diabetes and the Rationale for the active-comparator CAROLINA trial

Diabetes and Vascular Disease Research

10, 289-301

DOI: [10.1177/1479164112475102](https://doi.org/10.1177/1479164112475102)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2013, 382, 1413-1423.	6.3	162
2	Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glyceimic control. <i>Cardiovascular Diabetology</i> , 2013, 12, 129.	2.7	33
3	Drugs and diabetes: understanding the new breed of cardiovascular safety trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2013, 1, 175-177.	5.5	6
4	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 169.	1.1	135
5	Is Glyburide Safe in Pregnancy?. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 100-112.	0.9	13
6	Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data. <i>Diabetes Therapy</i> , 2014, 5, 483-498.	1.2	3
7	Alogliptin for the treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 547-559.	1.2	1
8	Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H477-H492.	1.5	92
9	Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 138-146.	1.0	96
10	Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin. <i>Diabetes Care</i> , 2014, 37, 2435-2441.	4.3	61
11	Cardiovascular disease prevention in diabetes: uncertainties and ethics. <i>Diabetes Management</i> , 2014, 4, 285-292.	0.5	0
12	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMEâ„†). <i>Cardiovascular Diabetology</i> , 2014, 13, 102.	2.7	198
13	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. <i>Postgraduate Medicine</i> , 2014, 126, 190-204.	0.9	11
14	Dipeptidyl Peptidaseâ€4 Inhibitors and Cardiovascular Outcomes: Metaâ€Analysis of Randomized Clinical Trials with 55,141 Participants. <i>Cardiovascular Therapeutics</i> , 2014, 32, 147-158.	1.1	111
15	Evaluating Cardiovascular Safety of Novel Therapeutic Agents for the Treatment of Type 2 Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2014, 16, 541.	1.3	14
16	DPP-4 inhibitors: pharmacological differences and their clinical implications. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 57-68.	1.0	588
17	Sitagliptin and the risk of hospitalization for heart failure: A population-based study. <i>International Journal of Cardiology</i> , 2014, 177, 86-90.	0.8	54
18	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	4.3	58

#	ARTICLE	IF	CITATIONS
19	Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1130-1146.	1.1	56
21	Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 587-610.	4.9	53
22	Cardiovascular safety of combination therapies with incretinâ€based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus â€ a retrospective nationwide study. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1001-1008.	2.2	43
24	Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. <i>Pharmaceutical Medicine</i> , 2014, 28, 109-117.	1.0	9
25	Potential cardioprotective action of GLP-1: from bench to bedside. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 979-988.	1.5	11
26	Linagliptin: from bench to bedside. <i>Drug Design, Development and Therapy</i> , 2014, 8, 431.	2.0	22
27	Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: A multinational, 24â€week, randomized, clinical trial. <i>Journal of Diabetes Investigation</i> , 2015, 6, 692-698.	1.1	20
28	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2015, 14, 57.	2.7	71
29	Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. <i>Cardiovascular Diabetology</i> , 2015, 14, 129.	2.7	66
30	Cardiovascular risks associated with secondâ€line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. <i>Diabetic Medicine</i> , 2015, 32, 1460-1469.	1.2	30
31	Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	42
32	Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. <i>European Heart Journal</i> , 2015, 36, 2288-2296.	1.0	210
33	Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges. <i>Current Cardiology Reports</i> , 2015, 17, 607.	1.3	24
34	Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials. <i>Diabetes Care</i> , 2015, 38, 948-950.	4.3	7
35	Linagliptin/metformin HCl (fixed combination therapy) for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 353-363.	1.2	0
36	Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety. <i>Advances in Therapy</i> , 2015, 32, 1065-1084.	1.3	8
37	A review of gliptins for 2014. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 43-62.	0.9	88
38	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 540-556.	0.9	69

#	ARTICLE	IF	CITATIONS
39	Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 305-317.	1.2	5
40	Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 505-524.	1.0	92
41	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA [®]). <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 164-174.	0.9	197
42	Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015. <i>Medicine Des Maladies Metaboliques</i> , 2015, 9, 158-163.	0.1	0
43	Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2015, 8, CMED.S10360.	1.0	14
44	Pharmacological cardioprotection in diabetes. <i>Diabetes Management</i> , 2015, 5, 89-101.	0.5	0
45	Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015, 38, 1145-1153.	4.3	73
46	Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 523-532.	2.2	66
47	Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2015, 75, 777-796.	4.9	24
48	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 154-163.	0.9	27
50	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2015, 127, 463-479.	0.9	11
51	Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors. <i>Postgraduate Medicine</i> , 2015, 127, 842-854.	0.9	5
52	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. <i>The Diabetes Educator</i> , 2015, 41, 19S-31S.	2.6	5
53	Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2015, 31, 1919-1931.	0.9	18
54	DPP-4 inhibitors: focus on safety. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 127-140.	1.0	55
55	Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 149-159.	1.0	8
56	Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 50-64.	0.8	20
57	Mortality risk among sulfonylureas: a systematic review and network meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 43-51.	5.5	180

#	ARTICLE	IF	CITATIONS
58	Practical combination therapy based on pathophysiology of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 355-369.	1.1	16
59	Diabetes Drugs and Cardiovascular Safety. <i>Endocrinology and Metabolism</i> , 2016, 31, 239.	1.3	12
60	Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications. <i>Hormones</i> , 2016, 15, 170-185.	0.9	7
61	The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials. <i>PLoS Medicine</i> , 2016, 13, e1001992.	3.9	101
62	Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition. <i>Journal of Cardiovascular Nursing</i> , 2016, 31, 274-283.	0.6	6
64	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	2.0	51
65	Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. <i>Diabetes Research and Clinical Practice</i> , 2016, 117, 39-47.	1.1	68
66	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1177-1185.	1.2	15
67	Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 171-182.	1.1	15
69	Follow the LEADERâ€™Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial. <i>Diabetes Therapy</i> , 2016, 7, 601-609.	1.2	10
70	Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. <i>Journal of Diabetes Investigation</i> , 2016, 7, 674-676.	1.1	7
71	Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1378-1384.	1.2	9
72	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. <i>Cardiology</i> , 2016, 135, 108-126.	0.6	5
73	Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study. <i>Diabetes Care</i> , 2016, 39, 726-734.	4.3	72
74	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 361-373.	1.1	37
75	DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 273-284.	1.1	19
76	Is gliclazide a sulfonylurea with difference? A review in 2016. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 839-851.	1.3	27
77	Novel Therapeutic Approaches in Diabetes. <i>Endocrine Development</i> , 2016, 31, 43-56.	1.3	15

#	ARTICLE	IF	CITATIONS
78	Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 126-130.	0.8	9
80	A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 13.	2.7	29
81	SGLT2 inhibitor/DPP-4 inhibitor combination therapy â€“ complementary mechanisms of action for management of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 409-420.	0.9	30
82	Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. <i>Diabetes Research and Clinical Practice</i> , 2017, 127, 224-237.	1.1	15
83	Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. <i>Endocrine Practice</i> , 2017, 23, 831-840.	1.1	11
84	The potential role and rationale for treatment of heart failure with sodiumâ€“glucose coâ€“transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
85	A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1399-1405.	1.0	7
86	Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes. <i>Medicine (United States)</i> , 2017, 96, e7213.	0.4	20
87	Satisfying the Regulatory Requirements for New Antidiabetic Drugs for Type 2 Diabetes Most Expeditiously. , 2017, , 251-275.		0
88	Cardiovascular events and allâ€“cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: <sc>A B</sc> ayesian metaâ€“analysis of survival data. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 329-335.	2.2	104
89	Cardiovascular Safety in Drug Development and Therapeutic Use. , 2017, , .		9
90	Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 694-704.	0.7	10
91	The safety of gliptins : updated data in 2018. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 387-405.	1.0	101
92	The heart failure burden of type 2 diabetes mellitusâ€“a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018, 23, 303-323.	1.7	41
93	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 821-832.	5.5	83
94	Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece. <i>Clinical Drug Investigation</i> , 2018, 38, 417-426.	1.1	34
95	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a<i>Diabetes Care</i>Editorsâ€™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
96	Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment. <i>Heart Failure Reviews</i> , 2018, 23, 469-479.	1.7	4

#	ARTICLE	IF	CITATIONS
97	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1379-1390.	1.2	50
98	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. <i>Diabetes Care</i> , 2018, 41, 39-48.	4.3	21
99	Renal outcomes with dipeptidyl peptidase-4 inhibitors. <i>Diabetes and Metabolism</i> , 2018, 44, 101-111.	1.4	19
100	Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review. <i>Cells</i> , 2018, 7, 181.	1.8	10
101	Documento de consenso de la Sociedad Española de Arteriosclerosis (SEA) para la prevención y tratamiento de la enfermedad cardiovascular en la diabetes mellitus tipo 2. <i>Clínica e Investigación En Arteriosclerosis</i> , 2018, 30, 1-19.	0.4	5
102	Managing Chronic Coronary Artery Disease in Patients with Diabetes. , 2018, , 355-373.		0
103	Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. <i>BMC Health Services Research</i> , 2018, 18, 78.	0.9	21
104	Cardiovascular Effects of New Oral Glucose-Lowering Agents. <i>Circulation Research</i> , 2018, 122, 1439-1459.	2.0	220
105	Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2378-2389.	1.1	31
106	Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2019, 4, CD012368.	1.5	21
107	Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1162-1171.	0.5	2
108	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1073-1078.	2.2	33
109	Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 60.	0.7	16
110	Management of hypoglycemia in older adults with type 2 diabetes. <i>Postgraduate Medicine</i> , 2019, 131, 241-250.	0.9	63
111	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154343.	1.5	36
112	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. <i>Diabetology International</i> , 2021, 12, 87-100.	0.7	12
113	Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3434.	1.7	5
114	Cardiovascular Benefits and Risk Profiles of Oral Anti-Diabetic Agents: Current Evidence and Ongoing Trials. <i>Journal of Cardiology and Therapy</i> , 2015, 2, 386-392.	0.1	1

#	ARTICLE	IF	CITATIONS
115	Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1818-1849.	1.0	22
116	Cardiovascular Outcomes and the Use of Oral Antidiabetic Drugs: A Review of Current Evidence from Observational Studies. <i>IJUM Medical Journal Malaysia</i> , 2020, 19, .	0.1	1
117	Newer oral and noninsulin therapies to treat type 2 diabetes mellitus. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S18-S26.	0.6	5
118	Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. <i>Indian Journal of Endocrinology and Metabolism</i> , 2015, 19, 577.	0.2	77
119	A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors. <i>Indian Journal of Endocrinology and Metabolism</i> , 2018, 22, 689.	0.2	19
120	Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. <i>World Journal of Diabetes</i> , 2015, 6, 1186.	1.3	9
121	Optimal utilisation of sulphonylureas in resource-constrained settings : review article. <i>Cardiovascular Journal of Africa</i> , 2014, 25, 83-85.	0.2	8
122	The prediction and assessment of cardiovascular and renal disease in type 2 diabetes. A current review. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2013, 20, 427-434.	0.3	1
123	Cardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?. <i>Journal of Diabetes Research & Clinical Metabolism</i> , 2015, 4, 3.	0.2	0
124	Combined Therapy with Antihyperglycemic Oral Agents (Metformin, Sulfonylureas) and Insulin in the Management of Type 2 Diabetic Patients (Pathogenic Substantiation and Clinical Utility). <i>MAĀĀnarodnij EndokrinologĀĀnjij ĀĀurnal</i> , 2016, .	0.1	0
125	Diabetes-Old Therapies Revisited. <i>Endocrinology&Metabolism International Journal</i> , 2016, 3, .	0.1	0
126	CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. <i>Meditinskiy Sovet</i> , 2017, , 32-37.	0.1	1
127	An observational study to assess the prevalence of cardiovascular disease in type 2 diabetes mellitus patients on treatment with oral antidiabetic drugs, at a Tertiary care hospital, in Chennai. <i>International Journal of Pharma and Bio Sciences</i> , 2018, 9, .	0.1	0
128	Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2021, 14, 117955142110516.	1.0	13
129	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 617-23.	0.2	6
130	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>Hippokratia</i> , 2015, 19, 195-9.	0.3	9
131	Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. <i>Indian Journal of Endocrinology and Metabolism</i> , 2014, 18, 617.	0.2	8